Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta‐analysis and systemic review

Yu‐Hung Chang; Dao‐Ming Chang; Kun‐Cheng Lin; Shyi‐Jang Shin; Yau‐Jiunn Lee

doi:10.1002/dmrr.1201

journal article Sep 01, 2011

Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta‐analysis and systemic review

Yu‐Hung Chang Dao‐Ming Chang Kun‐Cheng Lin Shyi‐Jang Shin Yau‐Jiunn Lee

Diabetes/Metabolism Research and Reviews Vol. 27 No. 6 pp. 515-527 · Wiley

View at Publisher Save 10.1002/dmrr.1201

Abstract

AbstractThere are controversies regarding the association of visfatin with overweight/obesity, type 2 diabetes mellitus, insulin resistance (IR), metabolic syndrome and cardiovascular disease in published articles. A meta‐analysis was performed to identify the significance of visfatin in these diseases. We searched for relevant articles in Pubmed, Scopus and SCIE. A total of 1035 articles were surveyed and 46 articles were identified, with 14 reports reporting more than one of our investigated diseases. A total of 13 (n = 644), 19 (n = 2405), 20 (n = 2249), 5 (n = 527) and 5 (n = 851) articles/(participants) were included in each meta‐analysis regarding the association of visfatin and overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases, respectively. Plasma visfatin concentrations were increased in participants diagnosed with overweight/obesity, type 2 diabetes mellitus, metabolic syndrome and cardiovascular diseases, with pooled log odds ratios of 1.164 [95% confidence interval (CI): 0.348 to 1.981, p = 0.005], 1.981 (95% CI: 1.377 to 2.584, p < 0.001), 1.094 (95% CI: 0.678 to 1.511, p < 0.001), and 2.902 (95% CI: 0.924 to 4.879, p < 0.005), respectively. The circulating visfatin level was positively associated with insulin resistance, with a Fisher's z of 0.089 (95% CI: 0.013 to 0.165, p = 0.022). No single study was found to affect the overall result of each analysis by sensitivity testing. No publication bias was found by the Egger test. Our study suggests that the use of visfatin may be promising for predicting obesity, diabetes status, insulin resistance, metabolic syndrome and cardiovascular disease. Copyright © 2011 John Wiley & Sons, Ltd.

Topics

No keywords indexed for this article. Browse by subject →

References

69

[1]

10.1126/science.1097243

[2]

10.1126/science.318.5850.565b

[3]

10.1210/jc.2005-1475

[4]

10.1055/s-2006-948309

[5]

10.1016/j.diabres.2006.07.031

[6]

10.2337/dc06-1581

[7]

Alghasham AA "Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy" Saudi Med J (2008)

[8]

10.1093/ndt/gfm828

[9]

10.1055/s-0028-1082040

[10]

10.1016/j.diabres.2010.11.003

[11]

10.1111/j.1440-1797.2009.01173.x

[12]

10.1055/s-0029-1237360

[13]

10.1016/j.diabres.2010.03.020

[14]

10.1016/j.metabol.2010.04.008

[15]

10.1210/jc.2005-1395

[16]

10.1111/j.1464-5491.2006.01909.x

[17]

10.2337/db06-0259

[18]

10.1016/j.metabol.2006.12.005

[19]

10.1055/s-2007-990288

[20]

10.1111/j.1365-2265.2008.03264.x

[21]

10.1016/j.metabol.2006.12.001

[22]

10.1530/eje-07-0127

[23]

10.1016/j.numecd.2007.09.001

[24]

10.1016/j.ejim.2007.05.014

[25]

10.1038/oby.2008.37

[26]

10.2337/db08-1176

[27]

10.1016/j.metabol.2007.04.007

[28]

10.1007/bf03346300

[29]

10.1111/j.1365-2265.2008.03248.x

[30]

10.1007/bf03346703

[31]

10.1016/j.regpep.2010.06.008

[32]

10.1111/j.1365-2265.2009.03674.x

[33]

10.1016/j.maturitas.2010.05.002

[34]

10.1111/j.1365-2265.2008.03453.x

[35]

10.1016/j.jstrokecerebrovasdis.2009.01.003

[36]

10.1210/jc.2006-0361

[37]

10.1093/ajcn/86.5.1310

[38]

10.1016/j.diabres.2009.03.016

[39]

10.1038/oby.2006.219

[40]

10.1111/j.1365-2265.2007.02751.x

[41]

10.1093/ajcn/85.2.399

[42]

10.1007/s00424-007-0262-y

[43]

10.1016/j.diabres.2007.04.016

[44]

10.1530/eje-07-0633

[45]

Erdem G "Therapeutic lifestyle change intervention in metabolic syndrome decreases plasma visfatin levels" Anatolian J Clin Investig (2008)

[46]

10.1111/j.1365-2362.2008.01964.x

[47]

10.1093/gerona/glq107

[48]

10.1016/j.metabol.2007.04.018

[49]

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults

JAMA 10.1001/jama.285.19.2486

[50]

International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome.2005;http://www.idf.org/webdata/docs/Metabolic_syndrome_definition.pdf.

Showing 50 of 69 references

Cited By

282

Nicotinamide phosphoribosyltransferase in NAD+ metabolism: physiological and pathophysiological implications

Weijia Zhang, Haoyu Ren · 2025

Cell Death Discovery

Impact of obesity on airway remodeling in asthma: pathophysiological insights and clinical implications

Aditya Sri Listyoko, Ryota Okazaki · 2024

Frontiers in Allergy

Biomarkers of Osteoarthritis—A Narrative Review on Causal Links with Metabolic Syndrome

Samuel James Lynskey, Marc Julian Macaluso · 2023

Life

NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential

Na Xie, Lu Zhang · 2020

Signal Transduction and Targeted Th...

NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation

Valentina Audrito, Vincenzo Gianluca Messana · 2020

Frontiers in Oncology

Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence

Luis Rajman, Karolina Chwalek · 2018

Cell Metabolism

The triad psoriasis–obesity–adipokine profile

S. Coimbra, C. Catarino · 2016

Journal of the European Academy of...

Metrics

282

Citations

69

References

Details

Published: Sep 01, 2011
Vol/Issue: 27(6)
Pages: 515-527
License: View

Authors

Division of Endocrinology and Metabolism, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan

Y

Yau‐Jiunn Lee

Cite This Article

Yu‐Hung Chang, Dao‐Ming Chang, Kun‐Cheng Lin, et al. (2011). Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta‐analysis and systemic review. Diabetes/Metabolism Research and Reviews, 27(6), 515-527. https://doi.org/10.1002/dmrr.1201

Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta‐analysis and systemic review

You May Also Like